The Horizon study is conducted by GSK, a global biopharma leader with new ambitions and new purpose: to unite science, technology, and talent to get ahead of disease together. This study has been reviewed by multiple boards and committees to protect the rights, safety, and well-being of people who take part in research studies.
We are seeking participants between the ages of 18 and 75 who are at risk for non-alcoholic steatohepatitis (NASH). If you have 2 or more of the following, you may be at risk for NASH, and you may qualify for this study:
- Hypertension
- Diabetes
- Dyslipidemia
- Metabolic Syndrome
- Fatty Liver on Ultrasound
- Overweight or Obese
- Abnormal Liver Tests (AST>20U/L)
- Over the age of 50
NASH is a condition affecting around 1 in 20 people or 5% of the world’s population. It occurs when fat that has built up in your liver causes damage and scarring of the liver. This study is being done to test if a potential new medicine can improve NASH.
If you qualify for the study and decide to join, you will come to the clinic approximately 19 times in a 76-week period. The study treatment will be administered every 4 weeks at the clinic. You may also need a liver biopsy to determine whether you are suitable to enter the study. An additional liver biopsy sample is required 52 weeks after the start of treatment. Blood samples will also be collected before the first study treatment injection and then every 4 weeks to monitor the effects of the study treatment, both good and bad. Scans will be performed periodically throughout the study to monitor changes in liver fat and scarring. Most visits will require a few hours of your time to complete all the study testing and to receive the study treatment.
If you meet the listed eligibility criteria and would like to learn more about the Horizon study, we would love to hear from you! To speak with the clinical research coordinator, please call (318) 525-3233.